BET inhibition as a new strategy for the treatment of gastric cancer
Gastric cancer is one of the most common malignancies and a leading cause of cancer death worldwide. The prognosis of stomach cancer is generally poor as this cancer is not very sensitive to commonly used chemotherapies. Epigenetic modifications play a key role in gastric cancer and contribute to th...
Main Authors: | Montenegro, R, Clark, P, Howarth, A, Wan, X, Ceroni, A, Siejka, P, Nunez-Alonso, G, Monteiro, O, Rogers, C, Gamble, V, Burbano, R, Brennan, P, Tallant, C, Ebner, D, Fedorov, O, O'Neill, E, Knapp, S, Dixon, D, Müller, S |
---|---|
Format: | Journal article |
Language: | English |
Published: |
Impacta Journals
2016
|
Similar Items
-
Identification of molecular targets for the targeted treatment of gastric cancer using dasatinib
by: Montenegro, RC, et al.
Published: (2020) -
Identification and development of 2,3-dihydropyrrolo[1,2-a]quinazolin-5(1H)-one inhibitors targeting bromodomains within the switch/sucrose nonfermenting complex
by: Sutherell, C, et al.
Published: (2016) -
Identification and development of 2,3-dihydropyrrolo[1,2-a]quinazolin-5(1H)-one inhibitors targeting bromodomains within the switch/sucrose non-fermenting complex.
by: Sutherell, C, et al.
Published: (2016) -
Chemical probes for bromodomains outside the BET family
by: Brennan, P, et al.
Published: (2013) -
Development of selective CBP/P300 benzoxazepine bromodomain inhibitors
by: Popp, T, et al.
Published: (2016)